Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-8554 mass balance study in healthy volunteers
NCT03381404Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elismetrep, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Total radioactivity in urine and faeces at 14 days, Maximum Observed Plasma Concentration at 14 days and 4 more. Started Dec 2017; status: completed.
02
Drugs
elismetrep
Beyond the preview
Go deeper on NCT03381404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381404.